1,117 reports of this reaction
2.6% of all MELPHALAN HYDROCHLORIDE reports
#9 most reported adverse reaction
THROMBOCYTOPENIA is the #9 most commonly reported adverse reaction for MELPHALAN HYDROCHLORIDE, manufactured by Fresenius Kabi USA, LLC. There are 1,117 FDA adverse event reports linking MELPHALAN HYDROCHLORIDE to THROMBOCYTOPENIA. This represents approximately 2.6% of all 43,335 adverse event reports for this drug.
Patients taking MELPHALAN HYDROCHLORIDE who experience thrombocytopenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THROMBOCYTOPENIA is a less commonly reported adverse event for MELPHALAN HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to thrombocytopenia, the following adverse reactions have been reported for MELPHALAN HYDROCHLORIDE:
The following drugs have also been linked to thrombocytopenia in FDA adverse event reports:
THROMBOCYTOPENIA has been reported as an adverse event in 1,117 FDA reports for MELPHALAN HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
THROMBOCYTOPENIA accounts for approximately 2.6% of all adverse event reports for MELPHALAN HYDROCHLORIDE, making it a notable side effect.
If you experience thrombocytopenia while taking MELPHALAN HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.